SCHEDULE: Valor Entities Report Reduced Stake in Harmony Biosciences

Valor Equity Partners and affiliated entities, including Antonio J. Gracias and Juan A. Sabater, have filed an amended Schedule 13G indicating their beneficial ownership in Harmony Biosciences Holdings, Inc. is now below 5% for all reporting persons.

Summary

• Valor Equity Partners IV L.P. beneficially owns 766,836 shares, representing 1.3% of Harmony Biosciences Holdings, Inc. common stock.
• Valor Equity Partners IV-B L.P. beneficially owns 396,651 shares, representing 0.7% of the common stock.
• Valor Equity Associates IV L.P. and Valor Equity Capital IV LLC each beneficially own 1,268,204 shares, representing 2.2% of the common stock.
• Valor Management L.P. beneficially owns an aggregate of 1,297,701 shares, representing 2.2% of the common stock, with 29,497 shares having sole voting and dispositive power, and 1,268,204 shares having shared voting and dispositive power.
• Antonio J. Gracias beneficially owns an aggregate of 1,831,327 shares, representing 3.2% of the common stock, with 533,626 shares having sole voting and dispositive power, and 1,297,701 shares having shared voting and dispositive power.
• Juan A. Sabater beneficially owns an aggregate of 1,392,250 shares, representing 2.4% of the common stock, with 94,549 shares having sole voting and dispositive power, and 1,297,701 shares having shared voting and dispositive power.
• Valor IV Pharma Holdings, LLC and Valor Equity Partners IV-A L.P. each report 0 shares and 0.0% beneficial ownership.
• The percentages are based on 57,596,358 shares of common stock outstanding as of October 31, 2025, as reported by Harmony Biosciences Holdings, Inc. in its Form 10-Q filed on November 4, 2025.

Sentiment

Score: 4

Explanation: The filing is a factual report of beneficial ownership. The reduction of reported stakes below the 5% threshold for all reporting persons, particularly for a group of institutional investors, could be viewed with slight caution as it may indicate a reduced conviction or a strategic divestment, though the filing itself provides no explicit reason.

Negatives

• The filing indicates that the reporting persons, individually and as a group, now hold less than 5% of the class, which could be interpreted as a reduction in their overall investment or influence in Harmony Biosciences Holdings, Inc.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The reduction in beneficial ownership by a significant institutional group could lead to questions about the long-term investment thesis of these entities, potentially influencing market perception and share price.

Key Dates

Keywords

Harmony Biosciences, Valor Equity Partners, Schedule 13G, Beneficial Ownership, Institutional Investor, Equity Stake, SEC Filing